- Home
- NUS vs BNTC Comparison
NUS vs BNTC Comparison
Compare NUS & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- BNTC
- Stock Information
- Founded
- NUS 1984
- BNTC 1995
- Country
- NUS United States
- BNTC United States
- Employees
- NUS N/A
- BNTC N/A
- Industry
- NUS Other Pharmaceuticals
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- BNTC Health Care
- Exchange
- NUS Nasdaq
- BNTC Nasdaq
- Market Cap
- NUS 361.7M
- BNTC 356.6M
- IPO Year
- NUS 1996
- BNTC N/A
- Fundamental
- Price
- NUS $8.63
- BNTC $15.36
- Analyst Decision
- NUS Hold
- BNTC Strong Buy
- Analyst Count
- NUS 2
- BNTC 7
- Target Price
- NUS $6.88
- BNTC $24.71
- AVG Volume (30 Days)
- NUS 655.1K
- BNTC 40.0K
- Earning Date
- NUS 05-08-2025
- BNTC 05-14-2025
- Dividend Yield
- NUS 2.78%
- BNTC N/A
- EPS Growth
- NUS N/A
- BNTC N/A
- EPS
- NUS N/A
- BNTC N/A
- Revenue
- NUS $1,679,268,000.00
- BNTC N/A
- Revenue This Year
- NUS N/A
- BNTC N/A
- Revenue Next Year
- NUS N/A
- BNTC N/A
- P/E Ratio
- NUS N/A
- BNTC N/A
- Revenue Growth
- NUS N/A
- BNTC N/A
- 52 Week Low
- NUS $5.32
- BNTC $5.74
- 52 Week High
- NUS $13.90
- BNTC $16.90
- Technical
- Relative Strength Index (RSI)
- NUS 73.05
- BNTC 61.26
- Support Level
- NUS $7.13
- BNTC $13.01
- Resistance Level
- NUS $7.68
- BNTC $16.55
- Average True Range (ATR)
- NUS 0.33
- BNTC 1.13
- MACD
- NUS 0.13
- BNTC 0.21
- Stochastic Oscillator
- NUS 82.70
- BNTC 72.00
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.